Please login to the form below

Not currently logged in

J&J aiming for above-average growth thanks to stream of blockbusters

US firm enters highly productive R&D phase


In just four years Johnson & Johnson (J&J) is expecting to have more than 10 new drugs filed or on the market with the potential to earn more than $1bn apiece per year.

The company showcased its pipeline to investors yesterday, with head of R&D William Hait and pharma chairman Joaquin Duato highlighting two late-stage drugs - anti-IL-23 antibody guselkumab for psoriasis and sirukumab, an IL-6 inhibitor for rheumatoid arthritis - that should be approved later this year.

Following on from these are a raft of drugs for cancer, central nervous system diseases and viral diseases that J&J sees as having great potential as it enters what would be the most productive R&D phase in the history of its biopharma division.

Among the highlighted cancer therapies are apalutamide (ARN-509) for pre-metastatic prostate cancer, an anti-androgen drug acquired via a $1bn deal with originator Aragon, an anti-IL3 receptor alpha antibody talacotuzumab for acute myeloid leukaemia (AML), FGFR blocker erdafitinib for solid tumours and PARP inhibitor niraparib - already approved as Zejula for ovarian cancer - for prostate cancer. J&J picked up commercial rights to niraparib (in prostate cancer only) from Tesaro for $500m last year.

Also name-checked in the R&D update was imetelstat for myelofibrosis, which J&J is co-developing with Geron for a number of indications under a $934m deal agreed in 2014. J&J is due to make a decision on the telomerase inhibitor later this year.

In the CNS sector J&J is heading for regulatory filings for esketamine for treatment-resistant depression, an intranasal formulation of the well-known tranquilizer and party drug ketamine. The NMDA antagonist won a breakthrough designation from the FDA last year, and J&J also sees big potential for JNJ-7922 an orexin-2 antagonist that is being developed as an adjunctive therapy for major depressive disorder.

The remaining two would-be blockbusters are both antiviral drugs. Lumicitabine for respiratory syncytial virus (RSV) infection was acquired by the company along with Alios BioPharma in 2014 for $1.75bn and has shown promise in clinical trials involving infants with RSV infection, while pimodivir (JNJ-3872) is a drug for influenza A acquired from Vertex.

Analysts said the preponderance of cancer therapies would help J&J meet its objective at growing sales by 5% a year through 2020, ahead of the background market growth by providing insulation against downward pricing pressure.

Article by
Phil Taylor

18th May 2017

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...